-
AboutShanxi Nuocheng Pharmaceutical Co., Ltd. was established in August 2008. It is located in Huairen High-tech Industrial Park, Shuozhou City, Shanxi Province. It is a national "high-tech enterprise" and the company covers an area of 330 acres.
-
ProductsOur company can produce anti-tumor, anti-fungal, antibiotics, nutrition, anesthesia, cardiovascular and cerebrovascular products such as 6 categories of series of products, the company's existing domestic products 73 product specifications and foreign products 22 product specifications.
-
NewsFrom 2019 to now, the company has attracted 38 kinds of generic drugs developed by 12 scientific research institutes such as Beijing Tongrentang Pharmaceutical Technology Development Co., Ltd. and Shanghai Rongdi Biotechnology Co., Ltd. to land in our company. After all of them are put into production, the annual output value can be increased by 1 billion and the profit can be about 0.2 billion.
-
ProductionThe API synthesis workshop includes 2 API production lines, 4 supporting warehouses and a 800 ㎡ sewage treatment station. The workshop has complete functions and can realize multi-product sharing. The existing API varieties are fluorenylmethoxycarbonyl-N-hydroxysuccinic acid imide ester (Fmoc-OSu), cinepazide maleate, fasudil, cimetidine, dimidamol, glycyrrhizic acid monopotassium salt and other 8 API varieties.
-
QualityAs a key construction project in Shanxi Province, we have been affirmed, cared and cared for by leaders at all levels. Leaders at all levels of the province, city and county have visited our company many times to guide the research work.
Good news! Shanxi Nuocheng Pharmaceutical Co., Ltd. obtained the production approval of fasudil hydrochloride raw materials and preparations.
Date:
2022-02-25
On November 24, 2021, the State Drug Administration announced the 115 drugs approved for listing, and Shanxi Nuocheng Pharmaceutical Co., Ltd.'s fasudil raw materials and injections were among them. This is another new achievement made by Norcheng Pharmaceutical. The landing of the new product approval not only reflects the overall strength of Norcheng Pharmaceutical in product research and development and registration, but also means that Norcheng Pharmaceutical's fasudil hydrochloride raw materials and injections will soon be sold domestically. Fasudil hydrochloride can improve and prevent cerebral vasospasm and cerebral ischemia after subarachnoid hemorrhage.
On November 24, 2021, the State Drug Administration announced the 115 drugs approved for listing, and Shanxi Nuocheng Pharmaceutical Co., Ltd.'s fasudil raw materials and injections were among them. This is another new achievement made by Norcheng Pharmaceutical. The landing of the new product approval not only reflects the overall strength of Norcheng Pharmaceutical in product research and development and registration, but also means that Norcheng Pharmaceutical's fasudil hydrochloride raw materials and injections will soon be sold domestically. Fasudil hydrochloride can improve and prevent cerebral vasospasm and cerebral ischemia after subarachnoid hemorrhage.
Key words:
Biopharmaceuticals
2023-07-02
Fuze the world, a promise will be made!
Norcheng Pharmaceuticals
Copyright©2023 Shanxi Nuocheng Pharmaceutical Co., Ltd.